LKB1 tumor suppressor regulates AMP kinase/mTOR-independent cell growth and proliferation via the phosphorylation of Yap

Oncogene

Volumn 32, Issue 35, 2013, Pages 4100-4109

  Nguyen, H B ^a   Babcock, J T ^a   Wells, C D ^a   Quilliam, L A ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

growth; Hippo; LKB1; polarity; Yap

Indexed keywords

ADENYLATE KINASE; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN; PROTEIN KINASE LKB1; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; YES ASSOCIATED PROTEIN;

ARTICLE; CANCER GROWTH; CELL GROWTH; CELL PROLIFERATION; CELL SIZE; CONTROLLED STUDY; DEGRADATION; HELA CELL; HUMAN; HUMAN CELL; KERATINOCYTE; MUTANT; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENYLATE KINASE; CELL PROLIFERATION; CELL SIZE; HELA CELLS; HUMANS; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN-SERINE-THREONINE KINASES; STRESS FIBERS; TOR SERINE-THREONINE KINASES; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 84883488932     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.431     Document Type: Article

References (45)

1. Bilder D. Epithelial polarity and proliferation control: links from the Drosophila neoplastic tumor suppressors. Genes Dev 2004; 18: 1909-1925.
2. Shackelford DB, Shaw RJ. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer 2009; 9: 563-575.
3. Zhao B, Li L, Lei Q, Guan KL. The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. Genes Dev 2010; 24: 862-874.
4. Hezel AF, Bardeesy N. LKB1; linking cell structure and tumor suppression. Oncogene 2008; 27: 6908-6919.
5. Gill RK, Yang SH, Meerzaman D, Mechanic LE, Bowman ED, Jeon HS et al. Frequent homozygous deletion of the LKB1/STK11 gene in non-small cell lung cancer. Oncogene 2011; 30: 3784-3791.
6. Lizcano JM, Goransson O, Toth R, Deak M, Morrice NA, Boudeau J et al. LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO J 2004; 23: 833-843.
7. van Veelen W, Korsse SE, van de Laar L, Peppelenbosch MP. The long and winding road to rational treatment of cancer associated with LKB1/AMPK/TSC/mTORC1 signaling. Oncogene 2011; 30: 2289-2303.
8. Baas AF, Kuipers J, van der Wel NN, Batlle E, Koerten HK, Peters PJ et al. Complete polarization of single intestinal epithelial cells upon activation of LKB1 by STRAD. Cell 2004; 116: 457-466.
9. Partanen JI, Nieminen AI, Makela TP, Klefstrom J. Suppression of oncogenic properties of c-Myc by LKB1-controlled epithelial organization. Proc Natl Acad Sci USA 2007; 104: 14694-14699.
10. Huang J, Wu S, Barrera J, Matthews K, Pan D. The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP. Cell 2005; 122: 421-434.
11. Pan D. The hippo signaling pathway in development and cancer. Dev Cell 2010; 19: 491-505.
12. Willecke M, Hamaratoglu F, Kango-Singh M, Udan R, Chen CL, Tao C et al. The fat cadherin acts through the hippo tumor-suppressor pathway to regulate tissue size. Curr Biol 2006; 16: 2090-2100.
13. Schlegelmilch K, Mohseni M, Kirak O, Pruszak J, Rodriguez JR, Zhou D et al. Yap1 acts downstream of alpha-catenin to control epidermal proliferation. Cell 2011; 144: 782-795.
14. Overholtzer M, Zhang J, Smolen GA, Muir B, Li W, Sgroi DC et al. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci USA 2006; 103: 12405-12410.
15. Zhang N, Bai H, David KK, Dong J, Zheng Y, Cai J et al. The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev Cell 2010; 19: 27-38.
16. Bertini E, Oka T, Sudol M, Strano S, Blandino G. YAPat the crossroad between transformation and tumor suppression. Cell Cycle 2009; 8: 49-57.
17. Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev 2007; 21: 2747-2761.
18. Zhao B, Li L, Tumaneng K, Wang CY, Guan KL. A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). Genes Dev 2010; 24: 72-85.
19. Mauviel A, Nallet-Staub F, Varelas X. Integrating developmental signals: a Hippo in the (path)way. Oncogene 2012; 31: 1743-1756.
20. Dickson MA, Hahn WC, Ino Y, Ronfard V, Wu JY, Weinberg RA et al. Human keratinocytes that express hTERT and also bypass a p16(INK4a)-enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics. Mol Cell Biol 2000; 20: 1436-1447.
21. Zhao B, Ye X, Yu J, Li L, Li W, Li S et al. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev 2008; 22: 1962-1971.
22. Basu S, Totty NF, Irwin MS, Sudol M, Downward J. Akt phosphorylates the Yesassociated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis. Mol Cell 2003; 11: 11-23.
23. Bettencourt-Dias M, Giet R, Sinka R, Mazumdar A, Lock WG, Balloux F et al. Genome-wide survey of protein kinases required for cell cycle progression. Nature 2004; 432: 980-987.
24. Huang H, Potter CJ, Tao W, Li DM, Brogiolo W, Hafen E et al. PTEN affects cell size, cell proliferation and apoptosis during Drosophila eye development. Development 1999; 126: 5365-5372.
25. Granot Z, Swisa A, Magenheim J, Stolovich-Rain M, Fujimoto W, Manduchi E et al. LKB1 regulates pancreatic beta cell size, polarity and function. Cell Metab 2009; 10: 296-308.
26. Camargo FD, Gokhale S, Johnnidis JB, Fu D, Bell GW, Jaenisch R et al. YAP1 increases organ size and expands undifferentiated progenitor cells. Curr Biol 2007; 17: 2054-2060.
27. Lian I, Kim J, Okazawa H, Zhao J, Zhao B, Yu J et al. The role of YAP transcription coactivator in regulating stem cell self-renewal and differentiation. Genes Dev 2010; 24: 1106-1118.
28. Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 2009; 284: 8023-8032.
29. Castro AF, Rebhun JF, Clark GJ, Quilliam LA. Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin-and farnesylation-dependent manner. J Biol Chem 2003; 278: 32493-32496.
30. Saucedo LJ, Edgar BA. Why size matters: altering cell size. Curr Opin Genet Dev 2002; 12: 565-571.
31. Sakamoto K, McCarthy A, Smith D, Green KA, Grahame Hardie D, Ashworth A et al. Deficiency of LKB1 in skeletal muscle prevents AMPK activation and glucose uptake during contraction. EMBO J 2005; 24: 1810-1820.
32. Wada K, Itoga K, Okano T, Yonemura S, Sasaki H. Hippo pathway regulation by cell morphology and stress fibers. Development 2011; 138: 3907-3914.
33. Dupont S, Morsut L, Aragona M, Enzo E, Giulitti S, Cordenonsi M et al. Role of YAP/TAZ in mechanotransduction. Nature 2011; 474: 179-183.
34. Zong H, Kaibuchi K, Quilliam LA. The insert region of RhoA is essential for Rho kinase activation and cellular transformation. Mol Cell Biol 2001; 21: 5287-5298.
35. Asuri S, Yan J, Paranavitana NC, Quilliam LA. E-cadherin dis-engagement activates the Rap1 GTPase. J Cell Biochem 2008; 105: 1027-1037.
36. Baas AF, Smit L, Clevers H. LKB1 tumor suppressor protein: PARtaker in cell polarity. Trends Cell Biol 2004; 14: 312-319.
37. Humbert N, Navaratnam N, Augert A, Da Costa M, Martien S, Wang J et al. Regulation of ploidy and senescence by the AMPK-related kinase NUAK1. EMBO J 2010; 29: 376-386.
38. Liu L, Ulbrich J, Muller J, Wustefeld T, Aeberhard L, Kress TR et al. Deregulated MYC expression induces dependence upon AMPK-related kinase 5. Nature 2012; 483: 608-612.
39. Bao Y, Nakagawa K, Yang Z, Ikeda M, Withanage K, Ishigami-Yuasa M et al. A cellbased assay to screen stimulators of the Hippo pathway reveals the inhibitory effect of dobutamine on the YAP-dependent gene transcription. J Biochem 2011; 150: 199-208.
40. Carretero J, Medina PP, Blanco R, Smit L, Tang M, Roncador G et al. Dysfunctional AMPK activity, signalling through mTOR and survival in response to energetic stress in LKB1-deficient lung cancer. Oncogene 2007; 26: 1616-1625.
41. Hauser CA, Westwick JK, Quilliam LA. Ras-mediated transcription activation: analysis by transient cotransfection assays. Methods Enzymol 1995; 255: 412-426.
42. Komuro A, Nagai M, Navin NE, Sudol M. WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxylterminal fragment of ErbB-4 that translocates to the nucleus. J Biol Chem 2003; 278: 33334-33341.
43. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307: 1098-1101.
44. Heller B, Adu-Gyamfi E, Smith-Kinnaman W, Babbey C, Vora M, Xue Y et al. Amot recognizes a juxtanuclear endocytic recycling compartment via a novel lipid binding domain. J Biol Chem 2010; 285: 12308-12320.
45. Ranahan WP, Han Z, Smith-Kinnaman W, Nabinger SC, Heller B, Herbert BS et al. The adaptor protein AMOT promotes the proliferation of mammary epithelial cells via the prolonged activation of the extracellular signal-regulated kinases. Cancer Res 2011; 71: 2203-2211.